Open Label, Adaptive, Parallel Group PET Study Using RO7017773 And [11C] RO15-4513

  • Autism Spectrum Disorder
Trial Status:

Completed

This trial runs in
Countries
  • United Kingdom
Trial Identifier:

NCT03507569 BP40257

      Show trial locations

      The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

      The below information is taken directly from the publicly available website ClinicalTrials.gov within a week of any updates, and has not been edited.

      Results Disclaimer

      Trial Summary

      This is a single dose (SD), non-randomized, open-label, adaptive, parallel group study with the purpose of investigating the occupancy of alpha5-containing GABAA receptors by RO7017773 in healthy participants.

      Hoffmann-La Roche Sponsor
      Phase 1 Phase
      NCT03507569 , BP40257 Trial Identifier
      RO7017773, [11C] Ro15-4513 Treatments
      Autism Spectrum Disorder Condition
      Official Title

      A Non-Randomized Open Label, Adaptive, Parallel Group, Human Positron Emission Tomography (PET) Study to Assess Occupancy of Brain alpha5-Containing GABAA Receptors of Ro7017773 Using [11C] Ro15-4513 Following Single Oral Doses in Healthy Participants

      Eligibility Criteria

      All Gender
      ≥ 23 Years & ≤ 55 Years Age
      Accepts Healthy Volunteers Healthy Volunteers
      Inclusion Criteria
      • Healthy (absence of evidence of any active or chronic disease following a detailed medical and surgical history, a complete physical examination including vital signs, 12-lead ECG, hematology, blood chemisty, serology, and urinalysis), as judged by the Investigator.
      • Males and women of non-childbearing potential (WONCBP)
      Exclusion Criteria
      • History of convulsions (other than benign febrile convulsions of childhood) including epilepsy, or personal history of significant cerebral trauma or CNS infections
      • Clinically significant abnormal finding from the MRI performed after the initial screening examination
      • Abnormal blood pressure, i.e, systolic blood pressure (SBP) greater than 140 or less than 90 mm Hg, and diastolic blood pressure (DBP) greater than 90 or less than 50 mm Hg
      • Abnormal pulse rate, resting pulse rate greater than 100 or less than 40 bpm
      • History or presence of clinically significant ECG abnormalities before study drug administration or cardiovascular disease
      • Show evidence of human immunodeficiency virus (HIV) infection and/or positive human HIV antibodies
      • Positive result on hepatitis B (HBV) or hepatitis C (HCV), presence of hepatitis B surface antigen (HBsAg) or positive hepatitis C antibody test result at screening or within 3 months prior to starting study treatment

      Clinical Research Explained

      Information about what clinical trials and observational studies are. Understand why you might want to take part in clinical research and why diversity in clinical research is important.

      Find out now